Search hospitals

>

Tennessee

>

Nashville

Sarah Cannon Research Institute

Claim this profile

Nashville, Tennessee 37203

Global Leader in Lung Cancer

Global Leader in Cancer

Conducts research for Solid Tumors

Conducts research for Breast Cancer

Conducts research for Pancreatic Cancer

670 reported clinical trials

29 medical researchers

Photo of Sarah Cannon Research Institute in NashvillePhoto of Sarah Cannon Research Institute in NashvillePhoto of Sarah Cannon Research Institute in Nashville

Summary

Sarah Cannon Research Institute is a medical facility located in Nashville, Tennessee. This center is recognized for care of Lung Cancer, Cancer, Solid Tumors, Breast Cancer, Pancreatic Cancer and other specialties. Sarah Cannon Research Institute is involved with conducting 670 clinical trials across 385 conditions. There are 29 research doctors associated with this hospital, such as Melissa Johnson, MD, Erika P Hamilton, Meredith A McKean, and Vivek Subbiah.

Area of expertise

1

Lung Cancer

Global Leader

Sarah Cannon Research Institute has run 192 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2 positive
2

Cancer

Global Leader

Sarah Cannon Research Institute has run 179 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2 positive

Top PIs

Clinical Trials running at Sarah Cannon Research Institute

Breast Cancer

Lung Cancer

Solid Tumors

Ovarian Cancer

Cancer

Pancreatic Cancer

Endometrial Cancer

Non-Small Cell Lung Cancer

Colorectal Cancer

Esophageal Cancer

Image of trial facility.

Imlunestrant

for Early Breast Cancer

This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.

Recruiting

2 awards

Phase 3

6 criteria

Image of trial facility.

Ribociclib + Hormone Therapy

for Breast Cancer

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Zanidatamab vs Trastuzumab

for Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.

Recruiting

2 awards

Phase 3

4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Sarah Cannon Research Institute?

Where is Sarah Cannon Research Institute located?

Who should I call to ask about financial aid or insurance network?

What insurance does Sarah Cannon Research Institute accept?

What awards or recognition has Sarah Cannon Research Institute received?